PETROS PHARMACEUTICALS INC (PTPI)

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

PTPI stock results show that Petros Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Petros Pharmaceuticals (NASDAQ:PTPI) just reported results for the second quart...

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024

PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc

NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Petros Pharmaceuticals Inc a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs.

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status